Targeted Agents in Esophagogastric Cancer Beyond Human Epidermal Growth Factor Receptor-2
Eric Mehlhaff1, Devon Miller1, Johnathan D Ebben1
1Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA.
Abstract:
Gastroesophageal cancers are highly diverse tumors in terms of their anatomic and molecular characteristics, making drug development challenging. Recent advancements in understanding the molecular profiles of these cancers have led to the identification of several new biomarkers. Ongoing clinical trials are investigating new targeted agents with promising results. CLDN18.2 has emerged as a biomarker with established activity of associated targeted therapies. Other targeted agents, such as bemarituzumab and DKN-01, are under active investigation. As new agents are incorporated into the treatment continuum, the questions of biomarker overlap, tumor heterogeneity, and toxicity management will need to be addressed.
Insights
Gastroesophageal cancers are diverse, but new biomarkers like CLDN18.2 and targeted therapies show promise. Future research will address biomarker overlap, heterogeneity, and toxicity in treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Gastroesophageal cancers exhibit significant anatomic and molecular diversity, complicating therapeutic strategies.
- Understanding tumor molecular profiles is crucial for advancing treatment options.
- Recent progress has identified novel biomarkers and targeted agents.
Purpose of the Study:
- To review advancements in understanding gastroesophageal cancer molecular characteristics.
- To highlight emerging biomarkers and targeted therapies in clinical development.
- To discuss challenges in integrating new treatments into clinical practice.
Main Methods:
- Literature review of recent advancements in gastroesophageal cancer research.
- Analysis of ongoing clinical trials for targeted agents.
- Discussion of identified biomarkers and their therapeutic implications.
Main Results:
- CLDN18.2 identified as a significant biomarker with demonstrated targeted therapy activity.
- Bemarituzumab and DKN-01 are among targeted agents under active investigation.
- Promising results from ongoing clinical trials indicate potential new treatment avenues.
Conclusions:
- Targeted therapies and biomarkers offer new hope for treating diverse gastroesophageal cancers.
- Addressing biomarker overlap, tumor heterogeneity, and toxicity is essential for successful treatment integration.
- Continued research is vital to optimize the use of novel agents in the treatment continuum.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:21Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...